Bone Biologics (BBLG) Debt to Equity (2016 - 2017)
Bone Biologics has reported Debt to Equity over the past 3 years, most recently at -$0.98 for Q4 2017.
- Quarterly Debt to Equity rose 6.45% to -$0.98 in Q4 2017 from the year-ago period, while the trailing twelve-month figure was -$0.98 through Dec 2017, up 6.45% year-over-year, with the annual reading at -$0.98 for FY2017, 6.45% up from the prior year.
- Debt to Equity was -$0.98 for Q4 2017 at Bone Biologics, up from -$1.97 in the prior quarter.
- Over five years, Debt to Equity peaked at -$0.98 in Q4 2017 and troughed at -$4.44 in Q1 2016.
- The 3-year median for Debt to Equity is -$1.97 (2017), against an average of -$2.15.
- The largest YoY upside for Debt to Equity was 46.06% in 2017 against a maximum downside of 6.45% in 2017.
- A 3-year view of Debt to Equity shows it stood at -$1.69 in 2015, then skyrocketed by 37.9% to -$1.05 in 2016, then grew by 6.45% to -$0.98 in 2017.
- Per Business Quant, the three most recent readings for BBLG's Debt to Equity are -$0.98 (Q4 2017), -$1.97 (Q3 2017), and -$1.97 (Q2 2017).